Matinas Biopharma Hl (MTNB) 0.8600 $MTNB Seeking Alpha's

New Post Public Reply Private Reply Replies (0) Message Board

May 18, 2015 at 11:41 PM

Matinas Biopharma Hl (MTNB) 0.8600 $MTNB

Seeking Alpha's Biotech Weekly: Celgene Check-Up, Is Gilead The New Apple?, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 17, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors geared up for earnings season, highlighted several...
SGYP: 3.90 (+0.38), BIIB: 395.42 (+4.18), ARWR: 6.18 (-0.11), AMGN: 163.44 (+1.08), MYL: 71.38 (+0.71), BMY: 68.00 (+0.36), CNCE: 14.20 (+0.07), CELG: 116.37 (+0.84), ATNM: 2.42 (-0.17), PFS: 18.35 (+0.31), NVIV: 12.09 (-0.97), GILD: 111.00 (+1.70), FWP: 33.99 (-0.66), GWPH: 112.93 (+0.68), IBM: 173.06 (-0.20), BAX: 68.25 (-1.11), AZN: 68.74 (-0.55), TEVA: 60.19 (-0.04)

Matinas' Pipeline Is Ready To Shine
Jason Napodano, CFA - Seeking Alpha - Thu Apr 16, 2:26PM CDT
By Jason Napodano, CFA On January 30, 2015, Matinas announced the establishment of a lipid-based, anti-infective platform with the acquisition of Aquarius BioTechnologies, Inc. This was the Bioral™ technology previously owned by BioDelivery...

Matinas BioPharma Completes Private Placement of $10 Million
GlobeNewswire - Fri Apr 10, 11:20AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"

(OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of lipid-based prescription therapeutics for the treatment of infectious diseases and cardiovascular and metabolic conditions, today announced that its President and Chief Executive Officer, Roelof Rongen, will be presenting on Monday, April 13, 2015, at 8:30 a.m. Pacific Daylight Time, at the 2 Annual Growth Capital Expo being held April 12-14, 2015, at Caesars Palace in Las Vegas, Nevada.

Apparent Connections To A Convicted Stock Promoter: Another Chapter In The Organovo Saga
Alpha Exposure - Seeking Alpha - Wed Apr 01, 12:16PM CDT
Much has been written about Organovo (NYSEMKT: ONVO ) and its shortcomings. Richard Pearson showed that Organovo's 3D liver tissue is not unique, that competitors are more advanced than ONVO, and that the market opportunity for liver assays is...
ONVO: 4.48 (-0.06)

Matinas BioPharma Completes Enrollment in First Human Trial of MAT9001
GlobeNewswire - Mon Mar 30, 7:05AM CDT
- Study Steering Committee Recommends Early Completion of Enrollment Due to Adequate Power in Study to Demonstrate Study Endpoints -

Matinas BioPharma to Present at the 17th Annual BIO CEO & Investor Conference on February 9, 2015
GlobeNewswire - Thu Feb 05, 7:07AM CST
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"

(OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of lipid-based prescription therapeutics for the treatment of metabolic and cardiovascular conditions and the treatment of infectious diseases, announced today that it will be presenting at the 17th Annual BIO CEO & Investor Conference being held February 9-10, 2015, at the Waldorf Astoria in New York, New York.

Matinas Biopharma Acquires Aquarius Biotechnologies
Jason Napodano, CFA - at Seeking Alpha - Wed Feb 04, 6:09PM CST

Matinas BioPharma Establishes Lipid-Based, Anti-Infective Platform, With Acquisition of Aquarius BioTechnologies Inc.
GlobeNewswire - Fri Jan 30, 7:25AM CST
- Novel lipid-crystal nano-particle cochleate formulation delivery platform with opportunity for broad use in anti-infectives featuring targeted delivery and multi-organ protection -

Matinas BioPharma Holdings, Inc. - Increasing Evidence That Elevated Triglycerides Cause Cardiovascular Events
ACCESSWIRE - Thu Jan 08, 12:18PM CST
New York, NY / ACCESSWIRE / January 8, 2015 / Matinas BioPharma Holdings, Inc. (OTCQB: MTNB) today published a new blog post on The Chairman's Blog, written by the Company's Co-Founder and CEO, Roelof Rongen. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Matinas BioPharma to Present at the Biotech Showcase 2015 Conference on January 14, 2015
GlobeNewswire - Wed Jan 07, 6:35AM CST
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"

(OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, announced today that Roelof Rongen, President and Chief Executive Officer, will be presenting at Biotech Showcase 2015 on Wednesday, January 14, 2015.

Matinas BioPharma Provides Update on Clinical Development Program for MAT9001 Following FDA Feedback on IND Submission
GlobeNewswire - Tue Dec 23, 7:05AM CST
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"

(OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, announced today that the Company has received advice and recommendations from the United States Food and Drug Administration (FDA) on its Investigational New Drug Application (IND) for its product candidate, MAT9001.

Eight Companies Webcast Live to Investors, December 4th at VirtualInvestorConferences.com
PR Newswire - Tue Dec 02, 7:29AM CST
CEOs and top executives to take questions in real-time during formal roadshow presentations as well as meet and "chat" in virtual trade booths
SMLR: 3.70 (+0.34), CRBP: 4.15 (+0.15), ONVO: 4.48 (-0.06), CYTX: 0.70 (+0.04), IAG: 2.29 (-0.02)

Matinas BioPharma Appoints Leading Clinical Lipid Specialist and Metabolism Researcher, Kevin C. Maki, Ph.D., to Scientific Advisory Board
GlobeNewswire - Mon Nov 24, 6:05AM CST
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"

(OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, announced today that it has appointed Kevin C. Maki, Ph.D. to its recently formed Scientific Advisory Board (SAB).

Matinas BioPharma to Present at Two Investor Conferences in Early December
GlobeNewswire - Thu Nov 20, 9:12AM CST
- LD Micro Main Event VII Presentation and Live Audio Webcast on Wednesday, December 3, 2014, at 3:00 p.m. PST / 6:00 p.m. EST -

Matinas BioPharma Commences Dosing in First Human Trial of Lead Product Candidate MAT9001
GlobeNewswire - Wed Nov 12, 6:35AM CST
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"

(OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced it has commenced dosing in the first-in-human study of MAT9001. The Company's initial trial is being conducted in Canada and is a pharmacokinetic and pharmacodynamic (PK/PD) study of MAT9001 versus an active comparator.

Matinas Biopharma Receives Notice of Allowance of U.S. Patent for MAT9001
GlobeNewswire - Mon Nov 10, 6:35AM CST
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"

(OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced it received a Notice of Allowance from the U.S. Patent and Trademark Office ("USPTO"

for U.S. Patent Application Serial No. 14/101,165 entitled, "Methods of Administering Compositions Comprising Docosapentaenoic Acid." Upon issuance, the patent will provide intellectual property protection through 2033.

Matinas BioPharma Appoints Cardiologist and Lipidology Expert Christie M. Ballantyne, M.D. to Scientific Advisory Board
GlobeNewswire - Tue Nov 04, 6:39AM CST
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"

(OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced that it has established a new Scientific Advisory Board (SAB) and appointed internationally renowned cardiologist Christie M. Ballantyne, M.D., as its first SAB member. The Company expects to add additional SAB members over the coming months.

Matinas BioPharma Receives Authorization From Health Canada to Initiate Human Clinical Study of Lead Product Candidate MAT9001
GlobeNewswire - Wed Oct 29, 6:35AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"

(OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced that it has received a Notice of Authorization from Health Canada to initiate the first-in-human study of MAT9001. The Company expects to commence dosing in this pharmacokinetic and pharmacodynamic (PK/PD) study of MAT9001 in Canada during the fourth quarter of 2014 and report topline data in the second quarter of 2015.

Matinas BioPharma Submits Investigational New Drug Application for Lead Product Candidate MAT9001 for the Treatment of Severe Hypertriglyceridemia
GlobeNewswire - Mon Oct 20, 8:38AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fluence Energy Faces Class Action: Investor Insights

Investor Blues: Fluence Under the Weather If you've been keeping an eye on Fluence Energy (NASDAQ:FLNC), you're probably clutching your metaphorical pearls right now. Here's the scoop: on November 2, 2026, the stock took another nosedive—dropping nearly 9%—as the company announced that both CEO Julian Nebreda and CFO Ahmad Pasha had packed their bags. A leadership...

Balancing Rigor and Interests in Education: Insights

Education: A Balancing Act of Academics and Interests So here's the deal, folks. Education isn't just about hitting the textbooks and acing exams. It's a wild dance—balancing rigorous academics and the extracurricular hustle. Brent Reckman, the brains behind The Academy of Charter Schools in Westminster, Colorado, knows this orchestra well. In a feature with...

Health Net Invests $3 Million in Stockton Housing

Putting a Roof Over Stockton's Head The talk of the town in Stockton is Health Net stepping up with a $3 million investment. This isn't just dropping loose change in a jar; it's about tackling a mammoth issue—making affordable housing more than just a pipe dream for 75 families. Community-driven, they say. What a cozy way to paint a picture of bridging that brutal gap...

Luvme Hair Offers Wig Variety for Winter Fashion

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Why Surge Protection Is Now a Vital Home Upgrade

Understanding the Hidden Risks of Power Surges You ever had a computer or TV go kaput out of the blue? Chances are, power surges are the stealthy culprit. Zachary Bobersky, an expert electrician from Ungerman Electric, dishes out the hard truths about how these electrical hiccups, often triggered by everyday use—like your refrigerator or AC flicking on—can quietly...

Toronto's Distillery Winter Village Kicks Off 2026

Toronto's Holiday Spirit Ignites Toronto just cranked up the holiday spirit with the lighting of a 55-foot Christmas tree at The Distillery Winter Village. Let me tell you, it's a sight that could warm your innards on the coldest winter night. Presented by Quince, this winter wonderland opened its doors for 2026—and it's looking like they're pulling out all the stops...

Hybrid Bonding Market Shooting to $2.45 Billion by 2033

Hybrid Bonding: The Future of Semiconductor Interconnects? Mark these words: Hybrid bonding isn't just another tech trend—it’s morphing into a billion-dollar juggernaut, my friend. With the latest numbers from MarketsandMarkets™, we see a potential leap from USD 0.38 billion in 2026 to a staggering USD 2.45 billion by 2033. We'll be seeing an eye-popping CAGR of...

BETR Investors Face Action: Nov. 20 Deadline Nears

High Stakes for BETR Shareholders If you're holding shares in Better Home & Finance Holding Company, right now might feel like you're at a craps table with emptying pockets. BETR, trading under NASDAQ, has become the center of a legal hurricane, with investors eyeing the November 20th deadline to join a securities class action led by Hagens Berman. The class period in...

Honoring Boston's Architects Changing the Game

Celebrating Architecture's Influencers in Boston Every now and then, a profession needs a wake-up call. Stirring the pot, shaking the roots, call it what you will, but when folks rally together with a shared vision, change doesn't just seem possible — it's inevitable. On November 12, the Boston Society of Architects (BSA) and Architecture in Common (AiC) did just that...

City National Bank Names New VP for Real Estate

Banking on Growth with Jeffrey LaBauve Jeffery LaBauve struts into the picture, ready to take the helm as City National Bank's new head of Commercial Real Estate Banking. And let me tell ya, the word on the street is he's raring to ramp things up. After almost two decades at Comerica Bank, this guy’s not here for a measly lap around the track—he's got plans to double...